NasdaqGM - Delayed Quote • USD
Corvus Pharmaceuticals, Inc. (CRVS)
At close: April 23 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-23,935.0000
-23,935.0000
-27,023.0000
-36,715.0000
-34,778.0000
Investing Cash Flow
15,541.0000
15,541.0000
-23,276.0000
21,560.0000
44,769.0000
Financing Cash Flow
7,855.0000
7,855.0000
--
62,158.0000
1,310.0000
End Cash Position
12,620.0000
12,620.0000
13,159.0000
63,458.0000
16,455.0000
Capital Expenditure
-34.0000
-34.0000
-269.0000
-5.0000
-76.0000
Issuance of Capital Stock
7,843.0000
7,843.0000
--
60,943.0000
1,222.0000
Free Cash Flow
-23,969.0000
-23,969.0000
-27,292.0000
-36,720.0000
-34,854.0000
12/31/2020 - 3/23/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
LPTX Leap Therapeutics, Inc.
3.2000
-0.31%
CLSD Clearside Biomedical, Inc.
1.3700
-2.84%
AFMD Affimed N.V.
5.35
+7.00%
CTMX CytomX Therapeutics, Inc.
1.6800
+0.60%
EPIX ESSA Pharma Inc.
6.40
0.00%
PDSB PDS Biotechnology Corporation
3.2000
+7.02%
CLRB Cellectar Biosciences, Inc.
3.1100
-2.51%
CGTX Cognition Therapeutics, Inc.
2.0000
+7.53%
GLYC GlycoMimetics, Inc.
1.8350
+1.94%
VINC Vincerx Pharma, Inc.
0.9500
+9.32%